Thank pandemic. operational you, impact with the update Steve. with of the the I'll COVID-XX start
work March partners. have Our care home concerns remains safety patients early instituted policy effect. the a from in been in our We that of and health primary employees, our
platforms, Fortunately, partners continuing development most in in teleconferences remain various to By of our we and to meeting have online programs. effective and our continue advance key been operation. using research
opening impact we of partial economic by mid-XXXX, pandemic limited our there operations. Assuming believe be on activities and of will
with of involved the even understand, activity for the disruptions prepared the is of be energy we the of resumption the on can in Palatin which a function inflammatory system, on based resurgence and has we this including and However, resolution balance, sexual virus, primary there focus intake, be business regulation to outcome. melanocortin of scientific will activities, further responses. food
regulating and its melanocortin function. work Food resulted a of by treatment first discovery as eventual successful for Administration the disorder. premenopausal based sexual desire suffering Our Drug and approval of Vyleesi the role on the was This with program hypoactive melanocortin in in women the sexual system system research
ability melanocortin inflammation. has research drugs that been developing target down turn or on to of recent resolve the system Our
We that inflammatory multiple candidates potential developed drug models variety of conditions. have preclinical a demonstrated the have to disease resolve
an processes. drugs shown resolution the melanocortin activities us conversion by others, resolution and IL-X as upregulation with from pro-inflammatory IL-XX. have and a targeting to mediating These of anti-inflammatory the of pro-inflammatory cytokines such that work of the cytokines, TNF-alpha, immune inflammatory include cells state, of of in pro the results and cells such production immune regulatory as Research others inhibition
the reducing role fibrotic plays in a response occurs many diseases. of In part addition, that the as melanocortin inflammatory system
health inflammatory diseases long-term the makes in The actions drugs. for as utility that patients. regulating melanocortin the exciting we multiple inflammatory have many in the from response of novel consequences target treating inflammatory immune the system believe negative it of melanocortin Therefore, an overactive occurs will target immune system that resulting for broad drugs diseases. that in the fibrosis The disease
have developed for drug candidates stage We diseases. clinical noninfectious as ocular such disease, retinal diseases and uveitis eye dry
We diseases also have gastrointestinal drug colitis. a cabinet for as clinical stage such ulcerative
eye immune known keratoconjunctivitis in sicca PL-XXXX drop first-line XXXX. important eye the drug formulation study a affects Phase placebo-controlled irritation, vision. also activating blurred that we locally, and eye and believe are reduce Problems eye aspects the inflammation cornea of and the targeting conjunctiva January by redness, target of that II Our the the as eye varied, many system, using melanocortin in dry system disease an the disease pain in will disease. dry of underlies resulting began Dry PL-XXXX
to penetration to to we study starting PL-XXXX in are the start study XXXX. of quarter the market the the are on patients running enrollment first Phase of were annual in are that which ophthalmic provide patient potential will to significant new and impact COVID-XX May the treatment If anticipate the is there us for will and with in of beginning been over patients efficacy market. studies, This study. demographics. opportunity hold. study will The growth treated, favorable and advance waiting June. enrollment number of first to able the in the eye successful allow substantial continued dry on and restart based and required prior for COVID-XX organization of of treatments data our allow a we their pandemic disease these that enroll commercial of research The in the have pandemic data complete with dry substantial June, we in have PL-XXXX We After enrolled will limited represents study believe in XXXX. eye billion and finish being we continued in expect and there on pivotal study, have tolerability $X in solution study, in study the will safety half sales Currently, patients group XXXX. to the a the contract the they the enroll believe the The III will patients discussions fourth market
or XXXX. uveitis are first a which and now due is and trials represents of the noninfectious pandemic. quarter the clinical scheduled in to begin This the second indication of half impact Our to retinal COVID-XX disease delay, X a to X
melanocortin We in are using scientific this inflammation. additional time to system in expand our understanding ocular
PL-XXXX. study PL-XXXX systemic a In ulcerative Phase we bowel our multiple combined ocular ascending oral release developed other a colitis clinical administered addition of single completed as X programs, treatment for subcutaneously formulation first inflammatory trials, the safety of evaluate dose We've I an diseases. to and PL-XXXX to colon have was ascending and pipeline
and evaluated study of of delivery formulation second The the oral pharmacokinetics the safety PL-XXXX. colon
placebo-controlled start in XXXX. represents patients. invest ulcerative to with proof-of-principles to the II study half clinical the half an second of the This to pandemic. planning delay XXXX readout are in X first of approximate We a in due This scheduled quarter study data Phase is colitis
in heart academic study ejection the in year be natriuretic an failure Phase proposed preserved agonist by with the anticipated calendar to and is Heart our study in The XXXX. with is fraction. of medical our half PL-XXXX a on now will IIa on peptide research Association patients major study work centers enrollment canvas brand. Based patient X collaboration system, peptide supported natriuretic receptor-A American The clinical evaluated drug a is second start in
administration on our other the manufacturing and with development drug with new continue to drug drug work schedule have the the limited activities required and research Fortunately, able impact pandemic. been to applications of preclinical investigational COVID-XX toxicology, and Food file
website can on our You additional on our information programs find www.palatin.com.
quickly global put immediate management Based care We that of partners. place and patients COVID-XX processes of to productive. to executive employees by uncertainty have ensure to and allowed actions the Board operations. the caused health remain adjust We extreme on safety took Directors our operational our pandemic, the highly our acted the employees, in business
from to continue to in cash to advance position. strong position ability pandemic our development Palatin allow healthy programs the a emerge Our our will and
Vyleesi resurgence. ensure by the of provided plans the that rights quarter remain intact. steps safeguard value North end the AMAG's calendar remains However, and of to of will diligent, our we We divestiture American by will the the XXXX, the putting Vyleesi to virus place agreement believe occur are in appropriate Vyleesi that license second taking of so we make
rapid I We you. would and begin novel our focused for will team partners all their developments, plant like strong In we to business pipeline drug thank closing, of activities of to adjustment remain advancement new continued and the our anticipate to progress novel dedication working Thank on clinical our drug the in and as will their candidates, continuing their normalize. Palatin accelerate have advancement to environment a which their development we candidates.
questions. for will We call now the open
